Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...

Fintel reports that on November 13, 2024, Brookline Capital downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that the SELECT-MDS-1 Phase 3 ...

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today.

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

Gainers: NATR +26%. AKBA +17%. ELMD +9%. SYRS +9%. NEPT +8%.Losers: ETRM -25%. MIRN -23%. IMUC -18%. PTX -17%. BVX -17%.Now read: Biotech Forum Daily Digest: Citron ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment... On Wednesday ...

Kia has officially revealed the name of its upcoming compact SUV and contrary to previous reports, it will be called “Syros”. Although Kia did file a trademark application for the “Syros ...

Short interest in Syros Pharmaceuticals Inc (NASDAQ:SYRS) decreased during the last reporting period, falling from 999.93K to 952.60K. This put 3.87% of the company's publicly available shares short.

Shortly after the teaser sketches of the new SUV were revealed, we have now got to know that it will be now called the Kia Syros. The name ‘Syros’ – which was trademarked by the carmaker in ...

Kia is set to expand its footprint in India’s SUV market with the launch of the Kia Syros—the first SUV under the company's new Kia 2.0 strategy. This model is expected to blend modern design ...